Prognostic and Predictive Factors for Renal Cell Carcinoma

• Published in: Targeted oncology Vol. 13; no. 3; pp. 309 - 331
• Main Authors: Suárez, Cristina, Campayo, Marc, Bastús, Romà, Castillo, Sergi, Etxanitz, Olatz, Guix, Marta, Sala, Núria, Gallardo, Enrique
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-06-2018; Springer Nature B.V
• Subjects: Biomedicine; Kidney cancer; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Review Article; Targeted cancer therapy
• ISSN: 1776-2596; 1776-260X
• DOI: 10.1007/s11523-018-0557-2

Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit. Some of them suggest a rational selection of patients to be treated with certain therapies, though none have been validated for routine use. This article provides an overview of both clinical and molecular factors associated with predictive or prognostic value in mRCC and emphasizes that both should be considered in parallel to provide the most appropriate, individualized treatment and achieve the best outcomes in clinical practice.